Skip to content

Heart failure

The current guidelines are AHA/ACC/HFSA 2022, and ESC 2021 with its 2023 focused update. Read the ESC 2021 and 2023 documents together: the update changes the HFmrEF, HFpEF, iron and post-discharge recommendations. No new AHA heart failure guideline has been published since 2022; the next one is expected around 2027.

AHA/ACC/HFSA 2022

International Current

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure

Official source

ESC 2021

International Current

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Official source

ESC 2023 focused update

International Current

2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Official source

Where they agree

  • The same LVEF categories: HFrEF ≤40%, HFmrEF 41–49%, HFpEF ≥50%.
  • The same natriuretic peptide cut-offs for suspecting HF in the non-acute setting: NT-proBNP ≥125 pg/mL or BNP ≥35 pg/mL.
  • Four drug classes for HFrEF, all Class 1/I: RAS inhibition (ARNI, ACEi or ARB), an evidence-based beta-blocker, an MRA and an SGLT2 inhibitor (dapagliflozin or empagliflozin). Add loop diuretics for congestion.
  • SGLT2 inhibitors across the whole EF range.
  • CRT for LVEF ≤35%, sinus rhythm, LBBB with QRS ≥150 ms (Class 1/I).
  • Ivabradine (2a/IIa) for sinus rhythm with heart rate ≥70 despite a beta-blocker. Digoxin and vericiguat are 2b/IIb.
  • Avoid: non-dihydropyridine CCBs, NSAIDs and thiazolidinediones in HFrEF.

Where they differ

AHA/ACC/HFSA 2022 ESC 2021 + 2023 update
Staging Stages A–D (at risk, pre-HF, symptomatic, advanced) NYHA class; no A–D staging
Improved EF Named category HFimpEF (previous ≤40%, now >40%): keep GDMT going Not a separate category
RAS inhibitor of choice in HFrEF ARNI first (1, A) for NYHA II–III; ACEi only if ARNI isn't feasible ACEi (I, A); ARNI as a replacement for ACEi (I, B); ARNI started without prior ACEi (de novo) is IIb
ICD, non-ischaemic, LVEF ≤35% 1 (A) IIa (A)
CRT, LBBB with QRS below 150 ms LBBB 120–149 ms: 2a LBBB 130–149 ms: IIa; not for QRS <130
HFmrEF: SGLT2i 2a I (2023)
HFpEF: SGLT2i 2a I (2023)
HFpEF: MRA / ARB / ARNI 2b each Not recommended (focus on comorbidities)
IV iron 2a in HFrEF I for symptoms and quality of life, IIa to cut hospitalisation (HFrEF and HFmrEF, 2023)
Hydralazine + isosorbide dinitrate 1 in African American patients, NYHA III–IV IIa in self-identified Black patients
After an HF admission – Intensive start and fast up-titration of GDMT before discharge and over 6 weeks (I, B; STRONG-HF, 2023)

Clinical pearls

  • "Four pillars" for HFrEF: ARNI/ACEi/ARB + beta-blocker + MRA + SGLT2i. Start them together or in quick succession, at low dose, then up-titrate.
  • ARNI–ACEi washout: 36 hours. Never give ARNI or ACEi to a patient with any history of angioedema.
  • Evidence-based beta-blockers: bisoprolol, carvedilol and metoprolol succinate (plus nebivolol in ESC).
  • MRA: eGFR >30 and K⁺ <5.0 to start (AHA). Stop if K⁺ can't be kept below 5.5.
  • Iron deficiency in HF: ferritin <100, or ferritin 100–299 with TSAT <20%.
  • CHAMPIT (ESC): the acute causes of HF to look for first. Coronary syndrome, Hypertensive emergency, Arrhythmia, Mechanical cause, Pulmonary embolism, Infection, Tamponade.